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ABSTRACT 
Bacteriophage therapy is a promising new treatment that may help overcome the threat posed 
by antibiotic-resistant pathogenic bacteria, which are increasingly identified in hospitalised 
patients. The development of biocompatible and sustainable vehicles for incorporation of 
viable bacterial viruses into a wound dressing is a promising alternative. This paper evaluates 
the anti-microbial efficacy of Bacteriophage K against Staphylococcus aureus over time, 
when stabilised and delivered via an oil-in-water nano-emulsion. Nano-emulsions were 
formulated via thermal phase inversion emulsification, and then bacterial growth was 
challenged with either native emulsion, or emulsion combined with Bacteriophage K. 
Bacteriophage infectivity, and the influence of storage time of the preparation, were assessed 
by turbidity measurements of bacterial samples. Newly prepared Bacteriophage K / nano-
emulsion formulations have greater anti-microbial activity than freely suspended 
bacteriophage. The phage loaded emulsions caused rapid and complete bacterial death of 
three different strains of Staphylococcus aureus. The same effect was observed for 
preparations that were either stored at room temperature (18 - 20°C), or chilled at 4°C, for up 
to 10 days of storage. A response surface design of experiments was used to gain insight on 
the relative effects of the emulsion formulation on bacterial growth and phage lytic activity. 
More diluted emulsions had a less significant effect on bacterial growth, and diluted 
bacteriophage-emulsion preparations yielded greater antibacterial activity. The enhancement 
of bacteriophage activity when delivered via nano-emulsions has yet to be reported. This 
prompts further investigation into the use of these formulations for the development of novel 
anti-microbial wound management strategies. 
 
Keywords: S. aureus infections, Phage therapy, oil-in-water nano-emulsion, burn wound 
related infections, responsive wound dressings. 
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INTRODUCTION 
 
The rise in antibiotic resistant bacteria such as methicillin resistant Staphylococcus aureus 
(MRSA) is widely reported1, but the rate of development of new antibiotics to treat these 
emerging ‘superbugs’ is low2. Only Linezolid has been approved for the treatment of acute 
skin infections since 20003, although Tedizolid is currently being developed4. Skin is the 
primary defence mechanism against infection5; hence injuries or burns constitute significant 
pathways for bacterial infection. Burns are especially susceptible to bacterial colonization 
with an estimated 10% of all burn injuries becoming infected6. Infection consequences 
include increased patient morbidity and mortality, and increased cost of treatment7,8 due to 
prolonged hospitalisation. Staphylococcus aureus (MRSA) is the most frequently detected 
antibiotic-resistant pathogen in hospitals worldwide9,10. The lack of effective new antibiotics 
has led to interest in alternative therapies11, including antimicrobial peptides12, microbial 
therapy, and the use of viruses that kill bacteria13,14. Such bacterial viruses, called 
bacteriophages or phages, attach to bacterial cell surfaces, use them as a host for their own 
replication, and eventually produce bacterial lysis. Bacteriophages therefore have potential 
for control of microbial infections15. 
Therapeutic use of bacteriophages dates from the 1930s and they are now being reconsidered 
as alternatives to antibiotics. The advantages of bacteriophage therapy include their capacity 
to infect bacterial cells, their abundance and ecological ‘friendliness’. They can be used as a 
‘phage-cocktail’, they multiply exponentially, and they do not affect human microflora and 
hence do not generate unwanted side-effects16. However, their broad diversity presents a 
challenge to our detailed understanding of their potential17. Bacteriophages have been used 
against skin and wound infections, with success rates up to 90% against Staphylococcus 
aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa14. Phage cocktails have been 
shown to increase survival significantly in mice with burn wound injuries18, and used in ear 
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infections of dogs19. Once a safe phage or ‘phage-cocktail’ has been identified, the aim is to 
deliver it to the point of infection without losing efficacy, either during delivery or storage.  
Surface burns are normally treated via cleaning to remove dead tissue, and covering the burn 
in a dressing to promote re-epithelisation and reduce or prevent infection. Various anti-
microbial wound dressings are available, including ActicoteTM, a silver-containing dressing. 
However, recent analysis of anti-microbial wound dressings has queried their effectiveness 
compared to passive alternatives20. 
Nano-emulsions provide enhanced biocompatibility compared to emulsions as they require 
less surfactant, which may affect the skin at high concentration21. Additionally the small 
droplet size allows greater penetration and distribution through the skin compared to 
emulsions22,23. A benefit of nano-emulsions as carriers of bacteriophage is prevention of 
aggregation24 which can result in precipitation and loss of biological activity. Nano-
emulsions can also provide stability in long-term phage storage without a significant decrease 
in infectivity25. Oil-in-water emulsions enhance transdermal penetration, and depending on 
the composition and the use of thickeners, numerous formulations can be achieved. However 
screening the wide variety of potential emulsion formulations is a challenge when looking for 
biocompatibility so careful design of experiments is essential. The efficacy of encapsulation 
for delivery and storage of bacteriophage has been demonstrated26,27. Nevertheless, phage 
infectivity and survival may be influenced by formulation composition28–35, which can 
damage phage structural components. Phage may be exposed to abnormal environmental 
conditions such as the emulsion components themselves. Furthermore, the compounds 
present in the nano-emulsion may influence bacterial growth itself, and thus mask the 
specific effect of the phage.  
This work evaluates the in vitro anti-microbial efficacy of Bacteriophage K when stabilised 
in an oil-in-water nano-emulsion, compared to simple delivery as an aqueous dispersion. 
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Bacteriophage K is lytic for a wide range of S. aureus strains as well as other staphylococci – 
three strains are selected here. The emulsion / phage formulation will form the basis for 
development of a wound dressing or topical cream, containing stabilised phage.  
MATERIALS AND METHODS 
Chemicals 
Brij® O10 (Polyoxyethylene (10) oleyl ether), soybean oil, Tryptic soy broth (TSB), tryptic 
soy agar (TSA), NaCl, MgSO4·7H2O, Tris-Cl, and gelatine were purchased from Sigma-
Aldrich (Dorset, UK). Reverse Osmosis water was produced in the laboratory.  
Bacterial and bacteriophage strains 
Staphylococcus aureus strains H560, H325, and Btn766 (Bacteriophage K sensitive strains), 
and Bacteriophage K, were obtained from AmpliPhi Biosciences (Bedfordshire, UK). 
Emulsification method 
Thermal phase inversion emulsification was used36,37 to produce formulations containing 5% 
(w/w) soybean oil as the organic phase, 15% (w/w) Brij O10® as surfactant, and 80% (w/w) 
SM buffer (100 mM NaCl, 8 mM MgSO4·7H2O, 50 mM Tris-Cl, 0.002% (w/v) gelatin, pH 
7.5) as the aqueous phase. The relatively high concentration of emulsifier allowed the more 
pronounced effects on bacterial growth and bacteriophage infectivity to be detected during a 
shorter storage time. The presence of SM buffer as the aqueous phase resulted in smaller 
emulsion droplets (via the salting out effect) and stabilised pH to an appropriate value for 
bacteriophage storage. The emulsion components were initially sterilised by filtration, and 
formulation took place under aseptic conditions. Brij O10® was added to the corresponding 
amount of SM buffer under mixing, and the required amount of soybean oil was added. 
Stirring continued for at least one hour until a homogenous mixture was achieved (complete 
dissolution of emulsifier). The coarse emulsion was transferred into a round-bottom flask 
with a condenser and heated with a hot water bath until the Phase Inversion Temperature 
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(PIT, approximately 80°C) was reached, as indicated by the appearance of a clear or bluish 
colour. Finally the emulsion was cooled rapidly by immersion in an ice bath, while stirring, 
to avoid coalescence.  
Bacteriophage propagation and purification 
S. aureus H560 was used as a host for the propagation of Bacteriophage K. It was grown in 
10 ml TSB overnight with orbital agitation. 100 μl of actively growing culture was mixed 
with 40 μl of Bacteriophage K stock solution, i.e. suspended in SM buffer, and incubated for 
5 minutes at room temperature to allow bacteriophages to adsorb. 3 ml of top tryptic soy agar 
(TSB containing 1.5 % (w/w) of bacteriological agar) was added to the bacteria-
bacteriophage mixture and poured onto a TSA plate, which was incubated overnight. 3 ml of 
SM buffer were added to the resulting confluent lysis plate. This plate was incubated with 
gentle shaking for approximately 4 hours at room temperature (18-20°C). The phage-
containing liquid was removed, centrifuged and passed through a 0.22 μm filter to eliminate 
possible bacterial debris. The titre of the phage lysate was determined by plaque assay. 
Incorporation of bacteriophage into emulsions 
The introduction of Bacteriophage K into the emulsion required dilution of the phage lysate 
to a concentration that lead to a noticeable decrease in bacterial growth, as indicated by a 
reduction in optical absorbance. Dilutions were made using emulsion as both diluent and 
storage media. The final concentration of bacteriophage used for infectivity tests 
corresponded to a multiplicity of infection (MOI) of about 0.1. Bacteriophage-emulsion 
preparations were kept either at room temperature (18-20°C) or cold temperature (4°C) over 
ten days and their ability to infect bacteria was tested regularly. 
Plaque assays and colony counting 
Standard colony counting was used to quantify bacterial concentration (colony forming units, 
CFU ml-1) and standard plaque assays were used to measure bacteriophage concentration 
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(plaque forming units, PFU ml-1) using overnight cultures of the tested strain with an initial 
optical density (O.D) of 1 – 1.5 absorbance units (a.u) at 600 nm, or about 108 CFU ml-1. 
Plaque assays could only be used for the quantification of bacteriophage infectivity in buffer, 
as the effect of the emulsion on the growth of the bacterial lawn was not measurable via this 
technique. Therefore, a fair comparison between free phage suspension and phage-emulsion 
formulations was not possible via standard PFU counting.  
Measurement of turbidity of bacterial samples 
Visual PFU counting may lead to errors and lack of reproducibility, hence optical density 
measurement was used as an alternative, as the turbidity of bacteria cultures in TSB should 
be reduced by the lytic action of bacteriophage. Variation of optical density with time was 
measured in triplicate via 96 multi-well plates, using a micro-plate reader (SPECTROstar 
Omega, BMG LABTECH). Measurements took place overnight for approximately 15 hours 
at 37°C and 600 nm, as a simulation of bacterial growth and phage infection in the incubator. 
Measurement of infectivity of bacteriophage preparations 
Bacteriophage infectivity was followed by the decrease in optical density of bacterial 
suspensions. Bacterial growth was challenged with either aqueous suspensions of 
bacteriophage in SM buffer, or bacteriophage-emulsion preparation, all in triplicate. The 
initial concentration of bacteriophage was the same in each case and equivalent to a MOI of 
0.1. The initial bacterial concentration was equivalent to 1 a.u., corresponding to about 108 
CFU ml-1. As samples comprised 100 μl of the appropriately diluted overnight bacterial 
culture, and 100 μl of the corresponding bacteriophage formulation, the MOI was preserved. 
The optical density of samples was measured at 600 nm for approximately 15 hours at 37°C. 
The bacteriophage-emulsion formulation was stored for a 10 day period, and infectivity was 
measured over time by taking samples and running growth curves and measuring the final 
bacterial concentration after the 15 hour treatment for each sample.  
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Characterisation of emulsions and stability 
Droplet size can determine the stability of emulsions as it influences the possibility of 
coalescence or creaming. This was measured using a ZETASIZER Nano Series (Malvern 
Instruments), based on the principle of dynamic light scattering (DLS) and Brownian motion 
of particles. Samples needed to be suitably diluted in water or buffer before being subjected 
to measurement. The stability of emulsions was also tracked via measurement of optical 
density over time38 using the micro-plate reader.  
Surface response experimental design to evaluate the influence of emulsion formulation 
on bacterial growth and bacteriophage infectivity 
A mixture containing emulsion droplets, bacteriophage, and bacteria could result in complex 
interactions between any pair of components, or all three. To understand the relative 
influence of these three components, experiments were designed using Response Surface 
Methodology (RSM). The main objective was to evaluate the effect of emulsion droplet 
concentration on bacterial growth under different growth conditions, and to detect variations 
in bacteriophage infectivity when emulsion was present. RSM was selected as the 
relationship between these variables was initially unknown. Experiments were designed using 
Minitab16® (Minitab Statistical Software), and experiments were randomised to meet the 
statistical assumptions and reduce the effects of other factors. Initial concentration of bacteria 
and the bacteria : emulsion droplet ratio were the factors used to study bacterial growth in 
emulsion for each of the bacterial strains and the different levels selected for each factor are 
presented in Table 1. Growth rate and carrying capacity were the response variables 
characterised in relation to bacterial growth. Values for these parameters were estimated from 
the Verhulst (logistic) model of population growth (Equation 1). 
           [1] 
where N(t) is the concentration of bacteria (CFU ml-1), t is time (h), a is the growth rate of the 
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bacterial population (h-1), and C is the carrying capacity or maximum population size (CFU 
ml-1). The logistic growth curve was preferred as it gives a reasonable fit despite its 
simplicity39. Bacterial growth was measured by turbidity assays (600 nm) at 37°C with 
orbital agitation for 20 hours, under the conditions specified by the experimental design, 
using six replicates. Optical density growth curves were used to estimate the parameters in 
the integrated form of the Vershulst model (Equation 2) using Origin 8 software (OriginLab, 
Northampton, MA)40.  
            [2] 
Here OD(t) is optical density of bacteria at time t (a.u.) – equivalent to N(t) in Equation 1, t is 
time (h), a is the growth rate of the bacterial population (h-1), B is an integration constant, and 
C is the carrying capacity or maximum population size (a.u.) as before. A non-linear least 
squares error minimisation algorithm was used to estimate the parameter values. 
Three parameters were considered for the factorial study of bacteriophage infectivity: the 
initial concentration of bacteria, the bacteria : emulsion droplet ratio, and the initial 
concentration of bacteriophage for each of the bacterial strains. The factor levels are listed in 
Table 1. The response variable was the final concentration of bacteria after contact with the 
bacteriophage-emulsion preparation (20 hours). 
RESULTS AND DISCUSSION 
Characterisation of emulsions 
Nano-emulsions prepared using the PIT method were transparent, with a droplet size of about 
20 nm, as previously reported for this formulation (5% (w/w) Soybean oil, 15% (w/w) Brij 
O10® surfactant, 80% (w/w) SM buffer)41. Nano-emulsions remained clear and transparent 
to the naked eye during the 10 day testing period, and optical density was also constant. No 
clouding, phase separation or coalescence was observed when stored at room or cold 
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temperature. Nano-emulsion stability is not only caused by the small droplet size, but also by 
the narrow droplet size distribution36. 
Influence of emulsion on bacterial growth 
The measurements of bacterial OD were all performed in triplicate, with average values 
being plotted in Figures 1 to 3. One in five of the error bars (representing standard deviation 
of the replicates) are presented for clarity. Nano-emulsion and TSB are virtually transparent 
at 600 nm; however, their baseline OD was subtracted from the raw data and appropriate 
propagation of errors was performed.  
S aureus H560 (Figure 1) grew at an initial high rate in both TSB and in 1: 10 diluted nano-
emulsion. When S aureus H560 was grown in more concentrated emulsion (1:1 dilution) the 
growth rate is slower, with a lag period in the first two or three hours. No noticeable 
difference in final bacterial concentration was observed for S. aureus H560 growing in TSB 
and 1:10 diluted nano-emulsion, but there was a decrease of about 25% in the final OD at the 
stationary phase when S. aureus H560 was grown in emulsion diluted 1:1. Figure 2 shows 
that growth of S. aureus H325 in both 1:1 and 1:10 diluted emulsion results in similar growth 
rates and final bacterial concentration. The OD in the stationary phase was reduced by 46% 
when emulsion was present, if compared with normal growth in TSB. Figure 3 shows that S. 
aureus Btn766 growth differed from H560 and H325 mainly in the 1:1 diluted emulsion, with 
lag period of almost 5 hours, a concentration peak at about 9 hours, and a slight decline 
before the stationary phase. When Btn766 was grown in 1:1 or 1:10 emulsion dilutions the 
final bacterial concentration was about the same, at almost 33% less than in TSB.  
To summarise, strains H560, H325, and Btn766 experienced the slowest growth when they 
were grown in 1:1 diluted emulsion. The maximum concentration of bacteria achieved was 
also affected, mainly being reduced for strains H325 and Btn766 growing in 1:10 and 1:1 
nano-emulsion dilutions (Figures 2 and 3). The slight decrease in bacterial concentration at 
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the end of the measurement period was attributed to the gravitational deposition of bacteria 
on the wells. The growth was generally slower in the presence of emulsion, but there was no 
apparent overall growth inhibition or antimicrobial effect, which is supported by the 
literature42–44. The distinctive growth patterns for the three bacterial strains suggest that 
variations in growth might be related to the specific metabolism of each strain. Bacteria tend 
to grow in the aqueous phase of food-related emulsion formulations, and the presence and 
concentration of emulsion droplets constitutes an important factor that can influence bacterial 
growth45,46. The observed decelerating effect of emulsions on bacterial growth is supported 
by published work, where E. coli is shown to grow slower when higher concentrations of 
emulsion were present in the growth medium47. These authors summarise possible 
explanations for this phenomenon as being impeded diffusion of nutrients through the 
organic phase, spatial limitations between bacteria and emulsion droplets, and facilitated 
accumulation of waste products, leading to growth inhibition. Interactions between emulsion 
droplets and bacteria have been shown to take place mainly due to electrostatic interactions48. 
This paper shows that emulsions formulated with non-ionic surfactants did not show changes 
in droplet size, and concludes that interactions bacteria and emulsion droplets did not affect 
emulsion stability. In our work, a non-ionic surfactant was used and the emulsion droplet size 
was in the range of nanometres. This explains the lack of variation in emulsion transparency 
when bacteria were present. However, it is clear that appropriate controls are required when 
bacteriophage and bacteriophage-emulsion formulations are tested against S. aureus, if they 
are to be effectively compared. When bacteriophage infectivity was tested, bacterial growth 
in TSB was selected as the control, whilst bacterial growth in emulsion was chosen as the 
control for bacteriophage-emulsion formulation testing. In this way the killing effects of 
phage, measured via reduction in bacterial OD, may be effectively compared. The influence 
of nano-emulsions on bacterial growth also prevented the use of standard plaque forming unit 
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assays for the quantification of bacteriophage infectivity. This restricted the CFU and PFU 
counting methods to the determination of initial concentrations of bacteria and bacteriophage. 
Efficacy of bacteriophage preparation 
Measurements were performed in triplicate, and one in five of the error bars, representing the 
standard deviation of triplicates, for the data are shown for clarity. When S. aureus H560, 
H325 and Btn766 were challenged with bacteriophage-emulsion preparations different 
responses were observed. Figures 4 to 6 show that for all strains, bacteriophage stored in SM 
buffer had no significant killing effect on bacteria after nine days of storage. The growth 
curves of S. aureus in TSB ( ) and in the presence of bacteriophage ( ) show almost 
identical shapes, and they reach the same final concentration after 15 hours. For S. aureus 
H560 and Btn766 (Figures 4 and 6), bacterial concentration was dramatically reduced after 
the first five hours of treatment with bacteriophage-emulsion formulation ( ), when 
compared with bacterial growth in emulsion ( ). From hour 7 the concentration is close to 
zero, indicating almost complete lysis of bacterial cells. In Figure 5, S. aureus H325 
continues growing to about 8 hours, but the subsequent decrease in concentration shows a 
significant killing effect by 15 hours. Enhanced lytic activity of bacteriophage has been 
demonstrated when stored in nano-emulsions for nine days. No similar effect has been 
reported in the literature, except for mention of a higher bacteriophage titre achieved within 
an emulsion49. Bacteriophages may be protected against inactivation due to electrostatic 
interactions between bacteriophage surface proteins and nano-emulsion droplets50. This 
shielding mechanism, which could preserve lytic activity, and combined with more 
favourable contact between bacteriophage and bacteria in the presence of emulsion, could 
result in an enhanced killing effect. The literature suggests that certain surfactants (e.g. 
emulsan) do not interfere with phage binding to bacterial surfaces; moreover the binding 
occurs at the emulsion interface51.  
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Surface response experimental design to evaluate the influence of emulsions on bacterial 
growth and bacteriophage infectivity 
Enhancement of infectivity of Bacteriophage K against S. aureus by nano-emulsion has been 
demonstrated (Figures 4 – 6), but the mechanisms of enhancement are not specifically 
understood. Factorial experimental design followed by RSM analysis was used to identify the 
most influential variables in the system on bacterial growth and bacteriophage infectivity. 
Normal probability plots show a normal distribution of the residuals between RSM 
predictions and experimental data for the three responses: bacterial growth rate, bacterial 
carrying capacity, and final concentration of bacteria in the presence of bacteriophage-
emulsion formulations. The residuals align to a straight line with R2 = 0.99. The random 
distribution of the residuals demonstrates agreement with the desired normal distribution, 
although some outliers were found. This statistical analysis gives an idea of the effectiveness 
of RSM for the evaluation of the responses as a function of the input factors (Table 1). 
Bacterial growth may be influenced by attachment of emulsion droplets to the outer cell 
membrane, causing a switch in metabolism, for instance inducing anaerobic behaviour due to 
the lack of available oxygen, or depriving bacteria of nutrients present in the medium. 
Emulsion droplets may also contribute to more effective bacteria-bacteriophage interaction, 
creating a framework that reduces adsorption distances. These effects may combine to 
influence both bacterial growth and phage-bacterial binding mechanisms. The significance of 
the experimental factors was determined by the Fisher test, which compares the p-values 
from the statistical software with a fixed value, α, at the desired confidence level. In this case 
95% confidence was selected (α = 0.05), and the influence of any factor was considered 
significant if its corresponding p-value was < 0.05.  
The most influential factors on bacterial growth rate were the initial concentration of bacteria 
(p-value=0.000) and the dilution factor of emulsion (p-value=0.000). The physical meaning 
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of these is understandable, and the relationships are confirmed in Figure 7.  
For bacterial carrying capacity, the most influential factors were emulsion concentration (p-
value=0.000), and the interaction between the initial concentration of bacteria and the 
emulsion concentration, i.e. bacteria : emulsion droplet ratio (p=0.001). A different growth 
pattern was observed for H560, H325 and Btn766 bacteria - see Figures 1, 2 and 3. Carrying 
capacity was not influenced by initial concentration (p-value=0.057), as time was sufficient 
for consumption of all nutrient resources - Figures 1 to 3 indicate the stationary phase. 
When final bacterial concentration was tested against varying bacteriophage-emulsion 
preparations, the most important factor was initial bacterial concentration (p-value=0000). 
The interaction of these factors is shown in Figures 4, 5 and 6 via different patterns of 
growth. Interaction between initial bacteria concentration and emulsion dilution factor was 
also significant (p-value=0.001), suggesting that bacterial growth is inhibited by emulsion.  
The results for the growth rate and carrying capacity response variables are shown in Figure 
7. The R2 values are closer to 1 for strains H560 and H325 than for Btn766. This means that 
Btn766 growth pattern differs from the logistic curve, see Figure 3. Maximum bacterial 
growth rates for strain H560 in Figure 7A are observed for lower concentrations of emulsions 
and for smaller initial concentrations of bacteria. Competition for resources is less acute 
when a reduced number of cells coexist during their initial growth phase. The maximum 
growth rate for H560 was 1.46 – 1.73 h-1 in 1:10 diluted emulsion. The most effective 
emulsion concentration (dilution factor of 1:10) was the same for all strains, see Figures 7C 
and 7E for strains H325 and Btn766. For the more concentrated emulsion (1:1 dilution) the 
large number of droplets could inhibit nutrient uptake by the bacteria.  However, the 
optimum growth rate varies from strain to strain depending on the initial bacterial 
concentration. For all initial concentrations of bacteria, growth in more dilute emulsions 
yielded higher growth rates. The dilution factor of emulsions had a slight effect on bacterial 
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carrying capacity, supporting a greater capacity for the most diluted emulsion. In Figure 7B, 
7D and 7F, H560 achieved the maximum number of bacteria with the higher dilution factor 
(1:100) leading to a higher carrying capacity. A less obvious effect is seen with Btn766. 
To summarise, emulsion formulations with least effect on bacterial growth were those that 
were diluted, supporting the hypothesis that droplets might inhibit the uptake of oxygen or 
nutrients by bacterial cells. If the killing effect of bacteriophage in dilute emulsions is high 
compared to the enhanced lytic activity seen with more concentrated emulsion (1:1 dilution), 
then dilute formulations would be selected as they affect bacterial growth less. 
Figure 8 shows the minimum final bacterial concentration (OD) values, corresponding to a 
maximum killing effect. For H560 (0.5 a.u.), Figure 8A shows minima at a bacteriophage 
concentration of about 1×10-3 PFU ml-1 for 1:100 diluted emulsion, and about 1×10-4 PFU 
ml-1 for 1:10 diluted emulsion and undiluted emulsion. For H325 (0.5 a.u.), Figure 8D shows 
a minimal final bacterial concentration at a bacteriophage concentration of 1×10-3 PFU ml-1 
for all dilution factors of emulsion. For Btn766 (0.5 a.u.), Figure 8G, the minima were found 
at the most diluted bacteriophage preparation in undiluted emulsion. For all diluted emulsions 
a concentration of 1×10-5 PFU ml-1 seems optimal. Similar patterns were observed for all 
initial concentrations of the three strains, although the figures are not shown. 
Figures 8B, 8E and 8H show similar patterns for the initial concentration of bacteriophage for 
H560, H325 and Btn766 respectively. For all initial concentrations of bacteria, highest initial 
concentrations of bacteriophage (1×10-3 PFU ml-1) seem to have the highest killing effect, 
except for Btn766 (Figure 8H) where the optimum can be seen between 1×10-4 and 1×10-5 
PFU ml-1. The same patterns were observed for all dilution factors of emulsion, although this 
data is not shown. For smaller initial concentrations of bacteria, in Figures 8D and 8E, there 
is a regrowth effect indicates a threshold below which active therapy of bacteriophage is not 
possible 52–54. 
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Figures 8C and 8I show that for an initial bacteriophage concentration of 1×10-4 PFU ml-1, 
diluted emulsions give greater killing effect for medium to high initial concentrations of 
H560, and medium initial concentrations of Btn766. The killing effect of H325 at medium to 
high initial concentrations of bacteria is not affected by the emulsion dilution factor (Figure 
8F).  The highest and medium initial concentrations of bacteria gave the lowest final bacteria 
concentration, so more concentrated emulsions generally give the highest killing effect. 
Shelf-life of bacteriophage – emulsion preparations 
A relative killing effect was defined, Equation 3, to compare the lytic activity of 
bacteriophage in buffer suspension with bacteriophage-emulsion formulations. 
   [3] 
Optical density (OD) is equivalent to bacterial concentration. Hence, the relative killing 
effect is the difference in OD between normal bacterial growth (control) and bacterial growth 
in the presence of bacteriophage, normalised to 20 hours of treatment. The controls were 
different in the normal growth medium and in the emulsion environment. The relative killing 
effect will have values between 0 and 1, where 0 corresponds to no killing at all (for bacteria 
in the presence of bacteriophage or bacteriophage-emulsion preparation with or without 
bacteriophage), and a value of 1 means a total kill, irrespective of the treatment. 
Bacteriophage-emulsion formulations show enhanced antibacterial activity (relative killing 
effects close to 1) against the three strains of S. aureus when stored at room and cold 
temperatures. It has been shown that emulsion influenced bacterial growth, but this effect is 
eliminated by the use of bacterial growth in undiluted emulsion as an appropriate control. 
Figures 9A, B and C show no significant variations of bacteriophage-emulsion activity over a 
10 day period, while bacteriophage lytic activity shows oscillations, giving different results 
for every day of treatment, and for each temperature of storage.  
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CONCLUSIONS 
A novel approach for the efficient storage and delivery of Bacteriophage K for the treatment 
of Staphylococcus aureus infections is demonstrated. The nano-emulsion-bacteriophage 
preparations show enhanced antimicrobial activity, with reduced fluctuations in infectivity 
over time when compared to simple aqueous suspensions of bacteriophage. The nano-
emulsion-bacteriophage formulations were more stable and effective over time. The effects 
of emulsion and emulsion preparations on bacterial growth were used to indicate both more 
optimal formulations insight into key interactions. This work provides the basis for a viable 
product and prompts further research into the biological mechanisms within the system, and 
into formulations with enhanced biocompatibility and low cost.  
RSM analysis confirmed the influence of emulsion concentration on the growth patterns of S. 
aureus, and identified important system interactions. The interactions between emulsion 
droplets and bacteria require a better model than the logistic growth curve. RSM analysis of 
the final concentration of bacteria in the presence of bacteriophage-emulsion preparations 
shows the potential to optimise the concentration rations of the components to reach a 
balance between desired killing effect and stable emulsion formulation. 
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NOMENCLATURE 
 
A Bacterial growth rate (h-1) 
B Integration constant 
C Carrying capacity (CFU ml-1 or a.u.) 
CFU ml-1 Colony forming units per millilitre  
DLS Dynamic Light Scattering  
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MOI Multiplicity of infection 
MRSA Methicillin Resistant Staphylococcus aureus 
N(t) Concentration of bacteria (CFU ml-1) 
OD Optical Density (absorbance units, a.u.) 
PIT Phase Inversion Temperature (°C) 
PFU ml-1 Plaque forming units per millilitre 
RO Reverse Osmosis 
RSM Response Surface Methodology 
T Time 
TSA Tryptic soy agar 
TSB Tryptic soy broth 
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Table 1: Factors, Levels and Response for the RSM 
Factor Levels Response 
Initial bacterial 
concentration (Initial OD) 
1 High – 1 a.u. 
0 Medium – 0.5 a.u. 
-1 Low – 0.1 a.u. Bacterial growth rate, a (h-1) 
Carrying capacity, C (a.u.) Dilution factor of raw 
emulsion 
1 High – 1:1 
0 Medium – 1:10 
-1 Low – 1:100 
Initial bacterial 
concentration (Initial OD) 
1 High – 1 a.u. 
0 Medium – 0.5 a.u. 
-1 Low – 0.1 a.u. 
Final concentration of bacteria 
after 20 h, expressed as OD(t) 
(a.u.) 
Dilution factor of raw 
emulsion 
1 High – 1:1 
0 Medium – 1:10 
-1 Low – 1:100 
Dilution from 
bacteriophage stock 
1 High – 1:103 
0 Medium – 1:104 
-1 Low – 1:105 
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Figure Titles 
 
Figure 1: Concentration of S. aureus H560 over time, expressed as Optical Density at 600 
nm, at 37°C in TSB ( ), in undiluted emulsion ( ), and in diluted emulsion ( ). Data points 
are the mean value of triplicates, after discounting the OD of TSB and emulsion. Error bars 
are the standard deviation of experimental values; one in five error bars are shown. 
 
Figure 2: Concentration of S. aureus H325 over time, expressed as Optical Density at 600 
nm, at 37°C in TSB ( ), in undiluted emulsion ( ), and in diluted emulsion ( ).Data points 
are the mean value of triplicates, after discounting the OD of TSB and emulsion. Error bars 
are the standard deviation of experimental values; one in five error bars are shown. 
 
Figure 3: Concentration of S. aureus Btn766 over time, expressed as Optical Density at 600 
nm, at 37°C in TSB ( ), in undiluted emulsion ( ), and in diluted emulsion ( ). Data points 
are the mean value of triplicates, after discounting the OD of TSB and emulsion. Error bars 
are the standard deviation of experimental values; one in five error bars are shown. 
 
Figure 4: Concentration of S. aureus H560 over time, expressed as Optical Density at 600 
nm, in TSB ( ), in undiluted emulsion ( ), in the presence of bacteriophage K ( ), and in 
the presence of Bacteriophage K – emulsion preparation ( ). All preparations were stored at 
4°C and tested after 9 days of storage. Data points represent the mean value of triplicates, 
after discounting the OD of TSB and emulsion or SM buffer. Error bars are the standard 
deviation of experimental values; one in five error bars are shown. 
 
Figure 5: Concentration of S. aureus H325 over time, expressed as Optical Density at 600 
nm, in TSB ( ), in undiluted emulsion ( ), in the presence of bacteriophage K ( ), and in 
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the presence of bacteriophage K – emulsion preparation ( ). All preparations were stored at 
4°C and tested after 9 days of storage. Data points represent the mean value of triplicates, 
after discounting the OD of TSB and emulsion or SM buffer. Error bars are the standard 
deviation of experimental values; one in five error bars are shown. 
 
Figure 6: Concentration of S. aureus Btn766 over time, expressed as Optical Density at 600 
nm, in TSB ( ), in undiluted emulsion ( ), in the presence of bacteriophage K ( ), and in 
the presence of bacteriophage K – emulsion preparation ( ). All preparations were stored at 
cold temperature and tested after 9 days of storage. Data points represent the mean value of 
triplicates, after discounting the OD of TSB and emulsion or SM buffer. Error bars are the 
standard deviation of experimental values; one in five error bars are shown. 
 
Figure 7: RSM Contour Plots for bacterial growth rate and carrying capacity.  
Bacterial growth rate vs. dilution factor of emulsion and initial concentration of H560 (Panel 
A), H325 (Panel C) and Btn766 (Panel E). Carrying capacity vs. dilution factor of emulsion 
and initial concentration of H560 (Panel B), H325 (Panel D) and Btn766 (Panel F). Six 
replicates for each of the design combinations of factors were performed. 
 
Figure 8: RSM Contour Plots for final concentration of bacteria in the presence of 
bacteriophage-emulsion preparations. Final concentration of bacteria vs: Panel A: dilution 
factor of emulsion and bacteriophage for an initial concentration of H560 of 0.5 a.u.; Panel B: 
dilution factor of bacteriophage and initial concentration of H560 at a dilution factor of 
emulsion of 1:10; Panel C: dilution factor of emulsion and initial concentration of H560 at a 
dilution factor of bacteriophage of 1:104; Panel D: dilution factor of emulsion and 
bacteriophage for  an initial concentration of H325 of 0.5 a.u.; Panel E: dilution factor of 
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bacteriophage and initial concentration of H325 at a dilution factor of emulsion of 1:10; 
Panel F dilution factor of emulsion and initial concentration of H325 at a dilution factor of 
bacteriophage of 1:104; Panel G: dilution factor of emulsion and bacteriophage for an initial 
concentration of Btn766 of 0.5 a.u.; Panel H: dilution factor of bacteriophage and initial 
concentration of Btn766 at a dilution factor of emulsion of 1:10; and Panel I: dilution factor 
of emulsion and initial concentration of Btn766 at a dilution factor of bacteriophage of 1:104. 
Six replicates were performed for each of the factor combinations. 
 
Figure 9: Bacteriophage K infectivity against S. aureus over a period of ten days, expressed 
as Relative Killing Effect, when stored in SM buffer at 18-20°C ( ), in undiluted emulsion 
at 18-20°C ( ), in SM buffer at 4°C ( ), and in undiluted emulsion at 4°C ( ). Panels 
A to C correspond to H560, H325 and Btn766 respectively. The bar height is the mean value 
of triplicates; error bars are the standard deviation of replicates. 
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